NCT03309202View on ClinicalTrials.gov

Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

June 26, 2018

Study Completion Date

July 18, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

PF-05221304

25 mg dose

Trial Locations (6)

32809

Orlando Clinical Research Center, Orlando

83101

Summit Clinical Research s.r.o., Bratislava

83305

Univerzitná Nemocnica Bratislava, Bratislava

B-1070

Pfizer Clinical Research Unit, Brussels

170 00

Pharmaceutical Research Associates CZ, s.r.o., Prague

180 81

Nemocnice Na Bulovce, Prague

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03309202 - Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment | Biotech Hunter | Biotech Hunter